Damian McNamara is a journalist at Medscape Medical News and MDedge. He specializes in medicine and healthcare, covering a range of topics including dermatology, endocrinology, immunotherapy, oncology, and remote healthcare. Damian's work has been featured in WebMD, Medscape, MDedge, and the University of Miami.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Damian Mcnamara's articles predominantly cover medical specialties, including dermatology and endocrinology. His focus is on informative content that often cites data or is data-driven. To effectively reach out to Damian, it would be beneficial to provide pitches supported by robust scientific evidence, such as new research findings or clinical trial results in the fields of dermatology and endocrinology.
Given his global focus but based in the United States, experts with international recognition or insights into how medical developments are impacting healthcare globally might capture his interest. Additionally, consider providing access to reputable sources for data and statistics when reaching out as this aligns with his coverage attributes.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Damian McNamara
Damian McNamara, MA March 28, 2026 DENVER – Topical roflumilast (Zoryve) cream 0.05% showed favorable efficacy and safety in children
The JAK1 inhibitor in development for treating nonsegmental vitiligo was superior to placebo on investigator ratings in two phase 3 trials.
A TYK2 inhibitor in development shows superior efficacy to placebo and apremilast for treating psoriasis, with no new safety concerns emerging.
A proof-of-concept study supports the safety and efficacy of rezpegaldesleukin vs placebo for treating severe-to-very-severe alopecia areata.
In the phase 2 trial, efficacy was also seen in patients with non-atopic chronic hand eczema treated with the oral JAK inhibitor.
Damian McNamara, MA April 27, 2026 DENVER — Recognizing the skin signs and risks associated with metabolic disease in dermatology
Researchers link the minimally invasive procedure to significantly greater total weight loss compared to lifestyle modification alone at 1 year after stopping GLP-1 therapy.
By: Damian McNamara
Edited by Damian McNamara May 08, 2026 TOPLINE:
CHICAGO — Two new studies have identified risk factors that may be associated with the increasing incidence of colorectal cancer (CRC) among younger Americans.
By: Damian McNamara
Damian McNamara, MA May 28, 2026 This is the second installment of a four-part series on biologics and dermatology, further exploring
